ZBH
Zimmer Biomet Holdings, Inc.Price & Indicators
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
TL;DR.
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders NeutralIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from its earnings releases, calls, and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Free cash flow non-GAAP | $245.9M | Q1 2026 | — |
| Net sales constant currency growth non-GAAP | 6.8% | Q1 2026 | — |
| Net sales organic constant currency growth non-GAAP | 2.9% | Q1 2026 | — |
| Share repurchases | $250M | Q1 2026 | — |
| adjusted EPS non-GAAP | $2.09 | first quarter 2026 call | — |
| international business growth non-GAAP | 2.5% | first quarter 2026 call | — |
| international hip sales growth non-GAAP | 1% | first quarter 2026 call | — |
| international knees growth non-GAAP | 1.3% | first quarter 2026 call | — |
| organic constant currency sales growth non-GAAP | 2.9% | first quarter 2026 call | — |
| SCP growth non-GAAP | 1.6% | first quarter 2026 call | — |
| U.S. business growth non-GAAP | 3.2% | first quarter 2026 call | — |
| U.S. hip franchise growth non-GAAP | 5% | first quarter 2026 call | — |
| U.S. knee growth non-GAAP | 2.2% | first quarter 2026 call | — |
| share repurchases completed | $250M | fourth quarter of fiscal 2025 | — |
Figures exactly as the company stated them · click a metric with a to chart its history · period links open the stating document · "call" marks figures stated on the earnings call, "filing" figures stated in the 10-K/10-Q · YoY needs the prior-year figure on file
Versus peers
Medical Devices — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
ZBH
this stock
Zimmer Biomet Holdings, Inc.
|
$17.26B | -2.1% | +7.2% | 23.1 | 6.0% |
|
ABT
Abbott Laboratories
|
$164.43B | -23.6% | +5.7% | 26.4 | 1.3% |
|
SYK
Stryker Corp
|
$125.30B | -6.8% | +11.2% | 37.8 | 1.6% |
|
MDT
Medtronic plc
|
$104.98B | -13.9% | +8.4% | 22.0 | 1.4% |
|
BSX
Boston Scientific Corp
|
$66.60B | -53.0% | +5.5% | 18.8 | 2.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| ZBH | +1.7% | +0.6% | -0.4% | +1.7% | -2.1% |
| SPY | -0.2% | +0.8% | +7.4% | -0.2% | +9.3% |
| vs SPY | +1.9% | -0.2% | -7.8% | +1.9% | -11.4% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.